-
1.发明授权
公开(公告)号：EP2928493B1
公开(公告)日：2019-08-07
申请号：EP13860021.8
申请日：2013-12-03
发明人： WU, Chia-Mao , CHANG, Hsiu-Kang
IPC分类号： A61K39/104
-
2.发明公开FUSION PROTEINS FOR USE AS IMMUNOGENIC ENHANCERS FOR INDUCING ANTIGEN-SPECIFIC T CELL RESPONSES 审中-公开融合蛋白作为免疫增强剂用于诱导抗原特异性T细胞应答
公开(公告)号：EP2928491A1
公开(公告)日：2015-10-14
申请号：EP13860917.7
申请日：2013-12-03
发明人： CHOU, Wei-I , WU, Chia-Mao , WU, Jiun-Ming , CHANG, Hsiu-Kang
IPC分类号： A61K39/104
CPC分类号： C07K14/005 , A61K39/12 , A61K39/135 , A61K39/17 , A61K39/21 , A61K39/29 , A61K39/292 , A61K39/385 , A61K2039/57 , A61K2039/585 , A61K2039/6031 , C07K14/21 , C07K14/70596 , C07K14/81 , C07K2319/02 , C07K2319/04 , C07K2319/095 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C12N9/1077 , C12N9/14 , C12N2710/20022 , C12N2710/20034 , C12N2730/10122 , C12N2730/10134 , C12N2750/10022 , C12N2750/10034 , C12N2760/18134 , C12N2770/24222 , C12N2770/24234 , C12N2770/24334 , C12N2770/32134 , C12Y204/02036 , C12Y306/05002 , Y02A50/386
摘要： A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.
摘要翻译： 公开了包含用于诱导增强的病原体抗原特异性T细胞应答的融合蛋白的疫苗组合物。 融合蛋白包含：（a）位于融合蛋白N端的抗原呈递细胞（APC）结合结构域或CD91受体结合结构域; （b）长度为34-112个氨基酸残基的易位肽，其包含与SEQ ID NO：4,2,3或6位于至少90％相同的氨基酸序列，位于 APC结合结构域或CD91受体结合结构域; 和（c）位于易位肽C-末端的病原体抗原; （d）包含SEQ ID NO：13的氨基酸序列的核输出信号; 和（e）位于融合蛋白C端的内质网滞留序列。
-
3.发明授权
公开(公告)号：EP2928491B1
公开(公告)日：2018-11-21
申请号：EP13860917.7
申请日：2013-12-03
发明人： CHOU, Wei-I , WU, Chia-Mao , WU, Jiun-Ming , CHANG, Hsiu-Kang
IPC分类号： A61K39/104
CPC分类号： C07K14/005 , A61K39/12 , A61K39/135 , A61K39/17 , A61K39/21 , A61K39/29 , A61K39/292 , A61K39/385 , A61K2039/57 , A61K2039/585 , A61K2039/6031 , C07K14/21 , C07K14/70596 , C07K14/81 , C07K2319/02 , C07K2319/04 , C07K2319/095 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C12N9/1077 , C12N9/14 , C12N2710/20022 , C12N2710/20034 , C12N2730/10122 , C12N2730/10134 , C12N2750/10022 , C12N2750/10034 , C12N2760/18134 , C12N2770/24222 , C12N2770/24234 , C12N2770/24334 , C12N2770/32134 , C12Y204/02036 , C12Y306/05002 , Y02A50/386
摘要： A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.
-
公开(公告)号：EP2237794B1
公开(公告)日：2013-04-10
申请号：EP09709108.6
申请日：2009-01-23
发明人： LIAO, Chao-wei , CHANG, Hsiu-kang
CPC分类号： C07K14/21 , A61K39/12 , A61K39/21 , A61K2039/5254 , A61K2039/54 , A61K2039/545 , A61K2039/55566 , A61K2039/57 , C07K14/005 , C07K2319/00 , C07K2319/10 , C07K2319/40 , C12N2740/16122 , C12N2740/16134 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334
-
公开(公告)号：EP3515929A1
公开(公告)日：2019-07-31
申请号：EP17851378.4
申请日：2017-09-11
发明人： WU, Chia-Mao , WU, Jiun-Ming , LIN, Yi-Chia , LEE, Kung-Lung , KANG, Chia-Hao , CHIANG, Fu-Hsien , CHANG, Cheng-Yung , CHANG, Wei-Lun , LIN, Hsiang-Kai , PENG, Chia-Kuan , LIN, Wei-Hsiang , CHIU, Yi-Tsui
IPC分类号： C07K14/005 , C07K14/02 , C07K14/705 , A61K39/385
-
6.发明公开A VACCINE COMPOSITION COMPRISING AN IMMUNOGENIC PROTEIN AND COMBINATION ADJUVANTS FOR USE IN ELICITING ANTIGEN-SPECIFIC T-CELL RESPONSES 审中-公开包含免疫原性蛋白和组合佐剂的疫苗组合物用于诱导抗原特异性T细胞应答
公开(公告)号：EP3261667A1
公开(公告)日：2018-01-03
申请号：EP16756299.0
申请日：2016-02-24
发明人： WU, Chia-Mao , WU, Jiun-Ming , CHIU, Yi-Tsui , LIN, Yin-Ching , CHUANG, Hsien-Kai , HSIEH, Fu-Tan , CHEN, Kuan-Ming
CPC分类号： A61K39/39 , A61K38/164 , A61K38/1774 , A61K39/12 , A61K2039/545 , A61K2039/55511 , A61K2039/55561 , A61K2039/55572 , A61K2039/55577 , A61K2039/585 , A61K2039/6031 , A61K2039/6037 , C12N7/00 , C12N2710/20033 , C12N2710/20034 , C12N2710/20071 , Y02A50/386
摘要： Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.
-
7.发明公开FUSION PROTEINS FOR USE AS IMMUNOGENIC ENHANCERS FOR INDUCING ANTIGEN-SPECIFIC T CELL RESPONSES 有权融合蛋白使用免疫原性放大器诱导抗原特异性T细胞应答
公开(公告)号：EP2928493A4
公开(公告)日：2017-01-04
申请号：EP13860021
申请日：2013-12-03
发明人： WU CHIA-MAO , CHANG HSIU-KANG
IPC分类号： A61K39/104
CPC分类号： C07K14/005 , A61K39/12 , A61K39/135 , A61K39/17 , A61K39/21 , A61K39/29 , A61K39/292 , A61K39/385 , A61K2039/57 , A61K2039/585 , A61K2039/6031 , C07K14/21 , C07K14/70596 , C07K14/81 , C07K2319/02 , C07K2319/04 , C07K2319/095 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C12N9/1077 , C12N9/14 , C12N2710/20022 , C12N2710/20034 , C12N2730/10122 , C12N2730/10134 , C12N2750/10022 , C12N2750/10034 , C12N2760/18134 , C12N2770/24222 , C12N2770/24234 , C12N2770/24334 , C12N2770/32134 , C12Y204/02036 , C12Y306/05002
摘要： A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.
-
8.发明公开FUSION PROTEINS FOR USE AS IMMUNOGENIC ENHANCERS FOR INDUCING ANTIGEN-SPECIFIC T CELL RESPONSES 审中-公开融合蛋白使用免疫原性放大器诱导抗原特异性T细胞应答
公开(公告)号：EP2928491A4
公开(公告)日：2016-07-13
申请号：EP13860917
申请日：2013-12-03
发明人： CHOU WEI-I , WU CHIA-MAO , WU JIUN-MING , CHANG HSIU-KANG
IPC分类号： A61K39/104
CPC分类号： C07K14/005 , A61K39/12 , A61K39/135 , A61K39/17 , A61K39/21 , A61K39/29 , A61K39/292 , A61K39/385 , A61K2039/57 , A61K2039/585 , A61K2039/6031 , C07K14/21 , C07K14/70596 , C07K14/81 , C07K2319/02 , C07K2319/04 , C07K2319/095 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C12N9/1077 , C12N9/14 , C12N2710/20022 , C12N2710/20034 , C12N2730/10122 , C12N2730/10134 , C12N2750/10022 , C12N2750/10034 , C12N2760/18134 , C12N2770/24222 , C12N2770/24234 , C12N2770/24334 , C12N2770/32134 , C12Y204/02036 , C12Y306/05002
摘要： A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.
-
9.发明公开FUSION PROTEINS FOR USE AS IMMUNOGENIC ENHANCERS FOR INDUCING ANTIGEN-SPECIFIC T CELL RESPONSES 有权融合蛋白使用免疫原性放大器诱导抗原特异性T细胞应答
公开(公告)号：EP2928493A1
公开(公告)日：2015-10-14
申请号：EP13860021.8
申请日：2013-12-03
发明人： WU, Chia-Mao , CHANG, Hsiu-Kang
IPC分类号： A61K39/385 , A61K39/00 , A61K38/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/135 , A61K39/17 , A61K39/21 , A61K39/29 , A61K39/292 , A61K39/385 , A61K2039/57 , A61K2039/585 , A61K2039/6031 , C07K14/21 , C07K14/70596 , C07K14/81 , C07K2319/02 , C07K2319/04 , C07K2319/095 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C12N9/1077 , C12N9/14 , C12N2710/20022 , C12N2710/20034 , C12N2730/10122 , C12N2730/10134 , C12N2750/10022 , C12N2750/10034 , C12N2760/18134 , C12N2770/24222 , C12N2770/24234 , C12N2770/24334 , C12N2770/32134 , C12Y204/02036 , C12Y306/05002 , Y02A50/386
摘要： A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.
摘要翻译： 一种融合蛋白，其用作用于增强抗原特异性T细胞应答的免疫原性增强剂的是游离缺失盘。 所述融合蛋白包含：（a）关于抗原呈递细胞（APC）结合结构域或CD91受体结合结构域; （B）蛋白质转导结构域; 和（c）病原体的抗原，worin的APC结合结构域或CD91受体结合结构域位于融合蛋白的N-末端，和病原体的抗原位于的C末端 蛋白转导域。 所述蛋白转导结构域来自选自由的选择：（ⅰ）一种融合多肽，其包含一个T细胞致敏信号转导肽，左，和易位肽; （ⅱ）的T细胞致敏信号转导肽; 和（iii）的长度为34至112氨基酸残基的易位肽。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.01 秒)
